| |
| |
|
| Insider
Information: |
Greene Barry E |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
132,162 |
|
|
Indirect Shares
|
6,153,503 |
|
|
| Direct
Value |
$10,095,917 |
|
|
|
Indirect Value
|
$15,314,570 |
|
|
| Total
Shares |
6,285,665 |
|
|
| Total
Value |
$25,410,487 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alnylam Pharmaceuticals Inc |
ALNY |
President |
2020-09-09 |
70,343 |
2020-09-09 |
3,003 |
Premium* |
|
|
Regulus Therapeutics Inc. |
RGLS |
Director, 10% Owner |
2012-10-10 |
0 |
2012-10-10 |
6,150,500 |
Premium* |
|
|
Karyopharm Therapeutics Inc. |
KPTI |
Director |
2022-08-11 |
13,606 |
2015-04-02 |
0 |
Premium* |
|
|
Acorda Therapeutics Inc |
ACOR |
Director |
2018-05-21 |
1,273 |
2017-01-03 |
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
|
2022-11-10 |
46,940 |
2021-06-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SAGE |
Sage Therapeutics, Inc. |
President and CEO |
• • – |
2022-11-10 |
4 |
B |
$34.48 |
$500,022 |
D/D |
14,500 |
46,940 |
0.01 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2022-08-11 |
4 |
OE |
$1.49 |
$11,250 |
D/D |
7,576 |
13,606 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
President and CEO |
• • – |
2021-08-05 |
4 |
B |
$43.15 |
$1,020,054 |
D/D |
23,640 |
32,440 |
0.01 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
President and CEO |
• • – |
2021-06-16 |
4 |
B |
$56.32 |
$495,627 |
D/D |
8,800 |
8,800 |
0.01 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-09-09 |
4 |
AS |
$122.66 |
$5,487,594 |
D/D |
(44,530) |
70,343 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-09-09 |
4 |
OE |
$9.14 |
$407,004 |
D/D |
44,530 |
114,873 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-08-10 |
4 |
OE |
$42.22 |
$349,871 |
D/D |
4,931 |
67,167 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-07-16 |
4 |
GA |
$0.00 |
$0 |
D/D |
3,176 |
65,412 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-07-16 |
4 |
GA |
$0.00 |
$0 |
I/I |
155 |
155 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-07-16 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,486 |
0 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-07-07 |
4 |
OE |
$9.14 |
$203,502 |
D/D |
22,265 |
84,501 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-07-07 |
4 |
AS |
$159.99 |
$3,562,177 |
D/D |
(22,265) |
62,236 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-05-06 |
4 |
AS |
$149.99 |
$3,339,527 |
D/D |
(22,265) |
62,236 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-05-06 |
4 |
OE |
$9.14 |
$203,502 |
D/D |
22,265 |
84,501 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-04-07 |
4 |
D |
$104.75 |
$174,321 |
D/D |
(1,663) |
62,236 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-04-07 |
4 |
A |
$0.00 |
$0 |
D/D |
5,417 |
63,899 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2020-03-13 |
4 |
OE |
$0.03 |
$100 |
D/D |
3,030 |
6,030 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2019-10-23 |
4 |
AS |
$0.00 |
$0 |
I/I |
(5,544) |
3,486 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2019-10-23 |
4 |
A |
$0.00 |
$0 |
D/D |
5,544 |
58,482 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2019-10-22 |
4 |
OE |
$16.43 |
$967,941 |
D/D |
58,913 |
111,851 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2019-10-22 |
4 |
AS |
$89.99 |
$5,301,581 |
D/D |
(58,913) |
52,938 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2019-07-11 |
4 |
A |
$0.00 |
$0 |
I/I |
46 |
3,003 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2019-04-09 |
4 |
A |
$0.00 |
$0 |
I/I |
52 |
2,957 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2018-10-18 |
4 |
A |
$0.00 |
$0 |
I/I |
21 |
2,905 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2018-07-31 |
4 |
GA |
$0.00 |
$0 |
I/I |
9,030 |
9,030 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
